medigraphic.com
ISSN 1405-8871 (Print)

2020, Number 2

<< Back Next >>

Aten Fam 2020; 27 (2)

Neuropathic Pain and its Association with the Severity Rate of Insomnia in Patients with Type 2 Diabetes Mellitus

Flores ALP, Guerrero MAL, Herrera OIG

Language: Spanish
References: 21
Page: 71-75
PDF size: 179.15 Kb.


ABSTRACT

Objective: to determine the association between neuropathic pain and the severity rate of insomnia in patients between 55 to 75 years with type 2 diabetes mellitus (DM2). Methods: analytical cross-sectional study. 309 patients with dm2 of the Family Medicine Unit (FMU) no. 75 of the Mexican Institute of Social Security (imss) participated in Nezahualcóyotl, State of Mexico. The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) questionnaires were applied to assess the presence of neuropathic pain (monofilament) and the Insomnia Severity Index (ISI) for assessment of the nature, severity and impact of insomnia. Results: neuropathic pain was detected in 50.8% of cases, in 36.9% it was associated with subclinical insomnia, while in 35.7% it was linked to clinical (moderate) insomnia; in patients who had neuropathic pain and glycemic disorder (50.2%), a mild and moderate degree of insomnia was detected (p‹0.05). Conclusions: more than half of the patients with DM2, had neuropathic pain with some degree of insomnia. These findings are important to promote physical examination by monofilament and determine the quality of sleep of this population, in order to avoid multiple complications in the long term.


REFERENCES

  1. Dosenovic S, Jelicic A, Miljanovic M, Biocic M, Boric K, Cavar M, et al. Interventions for neuropathic pain: an overview of systematic reviews. Chronic pain med. 2017;125(2):643-652.

  2. Secretaria de salud. Cenetec. Guía de práctica clínica. Tratamiento farmacológico del dolor neuropático en mayores de 18 años. [Internet] México 2010. [Citado 2019 Oct 24]. Disponible en: http://www.cenetec.salud.gob/contenidos/gpc/ catalogoMaestro-GPC.html.

  3. Torres M. Dolor neuropático periférico localizado (DNL) Guía para el abordaje diagnóstico y terapéutico farmacológico del Impreso en España. [Internet] 2017. [Citado 2019 Oct 24] Disponible en: https://www.researchgate.net/publication/ 320274305

  4. Coyne K, Currie M, Donevan S, Cappelleri J, Hegeman R, Abraham L, et al. Discriminating between neuropathic pain and sensory hypersensitivity using the chronic pain questions (CPQ). Postgrad Med. 2017;129(1):22-31.

  5. Guerrero S, Gaona B, Cuevas L, Torre L, Reyes M, Shamah T, et al. Prevalencia de síntomas de sueño y riesgo de apnea obstructiva del sueño en México. Salud púb Méx. 2018;60(3):347-355.

  6. Clemente V, Gomes A, Mendes M, Marques D, Russo B, Serra J, et al. The European portuguese version of the insomnia severity index (ISI): Reliability, Validity and diagnostic accuracy. Sleep med. 2017;40:3185.

  7. Khan M, Aouad R. The effects of insomnia and sleep loss on cardiovascular disease. Sleep Med Clin. 2017;12(2):167-177.

  8. Arango D, Rincón H. Trastorno depresivo, trastorno de ansiedad y dolor crónico: Múltiples manifestaciones de un núcleo fisiopatológico y clínico común. Rev colomb psiquiat. 2018;47(1):46-55.

  9. Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson D, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clinical therapeutics. 2018;40(6):828-849.

  10. Holingue C, Wennberg A, Berger S, Polotsky V, Spira A. Disturbed sleep and diabetes: A potential nexus of dementia risk. Rev metabol clin and exper. 2018;84:85-93.

  11. Attal N, Bouhassira D, Baron R. Diagnosis and assessment of neuropathic pain through questionnaires. Lancet neurol. 2018;17:456-466.

  12. Short N, Schmidt N. Developing and testing a novel, computerized insomnia and anxiety intervention to reduce safety aids among an at-risk student sample: A randomized controlled trial. Behavior therapy. 2019;51:1-13.

  13. Ziegler D, Landgraf R, Lobmann R, Reiners K, Rett K, Schnell O, et al. Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in a educational initiative. Diab research and clin prác. 2018;139:147-154.

  14. Pentzek M, Santos S, Wollny A, Gummersbach M, Herber O, Schmitten J, et al. Which patients with type 2 diabetes mellitus are perceived as “difficult” by general practitioners?. Primary care diabetes. 2019;13:353-359.

  15. Cardinez N, Levblom L, Bai J, Lewis E, Abraham A, Scarr D, et al. Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian study of longevitity in Type 1 diabetes. J of Diab and its complic. 2018;32:660-664.

  16. American diabetes association. Standars of medical care in diabetes. Diabetes care. 2017;40:11-24.

  17. Hameed E. TyG index a promising biomarker for glycemic control in type 2 diabetes mellitus. Diab metabol synd: Clinical Research and reviews. 2019;13:560-563.

  18. Alemohammad Z, Mehrizi A, Haghighi K, Tehrani M, Larijani B. Quality of sleep in patients with type 2 diabetes mellitus. Sleep med. 2017;40(1):3-185.

  19. Ferini L. Neuropathic pain and sleep: a review. Pain ther. 2017;6(1):19-23.

  20. Barone D, Chokroverty S. Neurologic diseases and sleep. Sleep med clin. 2017;12:73-85.

  21. Oda A, Inagaki M, Tasaki K, Matsui K, Horiguchi T, Koike M. The concept of sleep ability and its effect on diabetes control in adults with type 2 diabetes. Can journal diab. 2019;43:329-335.




2020     |     www.medigraphic.com